Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma

“…Also in our series, we could not identify any OS with HER-2 amplification. Using qRT-PCR analysis on 17 laser-microdissected, paraffin-embedded OS samples, Fellenberg and colleagues found a 1.3-fold HER-2 expression value to be correlated with poor response to chemotherapy [31]. Again, we were not able to confirm these findings in our series: moderately elevated levels of HER-2 expression were detected in 6 of 44 investigated samples but were not associated with clinicopathological parameters including response to chemotherapy.…”

Down-regulation of the polymeric immunoglobulin receptor in non-small cell lung carcinoma: correlation with dysregulated expression of the transcription factors USF and AP2

“…[25]). This approach has been used to monitor changes in gene expression in human cancers, including colorectal carcinoma [26][27][28][29], oral squamous cell carcinoma [30], gastric carcinoma [31], osteosarcoma [32], melanoma [33] and a number of hematologic malignancies [34][35][36][37][38]. The Q-PCR approach is particularly well suited to the analysis of RNA from paraffin-embedded archival tissues where the conditions of fixation and the length of storage may vary widely.…”

Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis

“…Overexpression can be due to gene amplification as in the case of HER-2 in a proportion of breast cancers and for EGFR in some cases of NSCLC and glioblastomas [1][2][3]. Although a considerable body of literature documents HER-2 expression in osteosarcomas, the conclusion has been controversial [6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The reasons for the conflicting results are most likely multifactorial and include lack of staining uniformity, that is, manual versus automated, clone of HER-2 antibody, and the different scoring systems applied by different investigators assessing HER-2 positivity despite established HER-2 scoring.…”

“…The results of investigations of HER-2 protein expression in osteosarcomas are highly variable. An increase in HER-2 expression and the correlation of this finding with poor clinical outcome [6][7][8][9][10][11][12] or with increased disease-free and overall survival [13] have been reported by some investigators. Other investigators were unable to demonstrate HER-2 expression [14][15][16][17][18][19].…”

“…To determine whether osteosarcomas contained mutations within the TK domain of EGFR, we sequenced exons 18 to 21 from tumor tissues of 10 patients with strong positive (3+) immunoreactivity for EGFR (patients 10,17,18,20,26,27,30,32,33, and 35; Table 1). One patient (patient 30) contained 2 base changes in exon 21.…”